Autologous expanded CD34+ stem cell therapy

Unassigned

New Medicines

ProtheraCytes · Myocardial infarction (MI) in patients with left ventricle ejection fraction below or equal to 45%

Information

ProtheraCytes
Advanced therapy medicinal product (ATMP)
CellProthera
CellProthera

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
None

Category

Suspension of expanded CD34+ stem cells conditioned in 3 syringes for an autologous endocardiac injection.
It is estimated that about 103,000 people in the UK have a myocardial infarction each year. About 60% occur in men [1].
Myocardial infarction (MI) in patients with left ventricle ejection fraction below or equal to 45%
Intracardiac